Amarin’s main strengths are a strong balance sheet with ample liquidity and very low debt, a clinically validated cardiovascular product with guideline support, and solid gross margins that show the underlying economics of the drug are attractive before overhead. The company benefits from brand recognition among specialists, differentiated science relative to commodity fish oil products, and longer patent protection along with partner‑based commercial models in many international markets. Its conservative capital structure gives it time and flexibility to adjust its business model.

Key risks include persistent operating and net losses, ongoing negative free cash flow, and a long history of accumulated deficits. The business is highly concentrated in a single product and therapeutic area, leaving it exposed to competitive, regulatory, and reimbursement shocks. U.S. generic competition has already damaged pricing power and could worsen over time, and international growth may be slower or more volatile than hoped. If cash burn continues without a meaningful improvement in profitability, the company may eventually need to raise additional capital, potentially diluting existing shareholders.

Looking ahead, Amarin’s trajectory will likely be shaped by its ability to stabilize revenue in the face of U.S. generic erosion and to unlock meaningful, higher‑margin growth from international markets through its partners. The strong balance sheet provides a runway to pursue this strategy, but the income statement and cash flows indicate that operational restructuring and disciplined cost control remain important. If the company can leverage its clinical data and patents to build a durable global franchise while bringing expenses in line with its new revenue reality, its financial profile could gradually improve; if not, pressure on cash and long‑term value could intensify. Uncertainty is therefore elevated, and outcomes will hinge on execution and market reception outside the U.S.